INAB

+ Watchlist + Portfolio

IN8bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.20
52-Week Range: $0.88 – $2.73
Market Cap: $11.93M
P/E (TTM): —
EPS (TTM): -1.30
Dividend Yield: —

Advanced Metrics

Price/Book: 0.65
PEG Ratio: —
Return on Equity: -111.11%
Return on Assets: -58.37%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 8.21
Debt/Equity: 0.12
Total Debt: $2.18M
Free Cash Flow: $-7.92M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-3.95M

INAB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$14.06M	$16.83M	$16.96M	$10.21M
Selling, General & Admin	$14.46M	$13.51M	$12.64M	$9.65M
Operating Expenses	$28.52M	$30.01M	$29.60M	$19.86M
Operating Income	-$28.52M	-$30.01M	-$29.60M	-$19.86M
EBITDA	-$27.42M	-$27.51M	-$26.94M	-$17.36M
Pretax Income	-$28.52M	-$30.01M	-$30.44M	-$19.44M
Net Income	-$28.52M	-$30.01M	-$30.44M	-$19.44M
Diluted EPS	-40.80	-30.00	-17.05	-4.44
Diluted Shares	698931	995497	1.78M	4.37M

INAB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.18M	$21.28M	$11.12M	$27.09M
Current Assets	$22.23M	$24.63M	$12.58M	$27.88M
Total Assets	$33.04M	$33.71M	$20.94M	$32.28M
Current Liabilities	$5.82M	$5.39M	$3.08M	$3.16M
Total Debt	$5.87M	$4.89M	$5.03M	$2.78M
Total Liabilities	$10.31M	$8.77M	$6.47M	$4.72M
Retained Earnings	-$61.21M	-$91.22M	-$121.66M	-$141.10M
Shareholders' Equity	$22.73M	$24.94M	$14.48M	$27.56M
Working Capital	$16.41M	$19.23M	$9.49M	$24.72M

INAB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$24.12M	-$23.34M	-$24.15M	-$12.71M
Capital Expenditure	-$3.71M	-$600.00K	-$187.00K	—
Free Cash Flow	-$27.83M	-$23.94M	-$24.34M	-$12.71M
Depreciation & Amortisation	$1.10M	$2.50M	$2.65M	$2.50M
Stock-Based Compensation	$3.47M	$4.37M	$5.00M	$3.19M
Investing Cash Flow	-$3.71M	-$600.00K	-$187.00K	$0.00
Financing Cash Flow	$8.99M	$27.04M	$14.18M	$28.64M
Net Change in Cash	-$19.09M	$3.10M	-$10.15M	$15.93M

INAB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.97M	$2.49M	$2.10M	$2.65M	$2.61M
Selling, General & Admin	$2.69M	$2.71M	$1.86M	$2.38M	$2.65M
Operating Expenses	$5.66M	$5.20M	$3.97M	$5.03M	$5.27M
Operating Income	-$5.66M	-$5.20M	-$3.97M	-$5.03M	-$5.27M
EBITDA	-$4.99M	-$4.42M	-$3.44M	-$4.51M	-$4.77M
Pretax Income	-$5.55M	-$5.09M	-$3.85M	-$4.94M	-$5.09M
Net Income	-$5.55M	-$5.09M	-$3.85M	-$4.94M	-$5.09M
Diluted EPS	-2.10	-1.24	-0.85	—	-0.26
Diluted Shares	2.78M	4.12M	4.54M	—	19.47M

INAB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$11.89M	$13.23M	$10.69M	$27.09M	$21.94M
Current Assets	$12.72M	$13.74M	$11.77M	$27.88M	$22.66M
Total Assets	$19.87M	$19.37M	$16.77M	$32.28M	$26.27M
Current Liabilities	$2.96M	$1.95M	$1.70M	$3.16M	$2.16M
Total Debt	$4.27M	$3.12M	$2.96M	$2.78M	$2.35M
Total Liabilities	$5.99M	$4.13M	$3.58M	$4.72M	$3.48M
Retained Earnings	-$127.21M	-$132.30M	-$136.15M	-$141.10M	-$146.19M
Shareholders' Equity	$13.88M	$15.24M	$13.19M	$27.56M	$22.78M
Working Capital	$9.77M	$11.79M	$10.06M	$24.72M	$20.50M

INAB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.12M	-$3.93M	-$3.52M	-$2.14M	-$4.95M
Capital Expenditure	—	—	—	—	-$9.00K
Free Cash Flow	-$3.12M	-$3.93M	-$3.52M	-$2.14M	-$4.96M
Depreciation & Amortisation	$669.00K	$784.00K	$527.00K	$521.00K	$500.00K
Stock-Based Compensation	$831.00K	$955.00K	$692.00K	$711.00K	$401.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	-$9.00K
Financing Cash Flow	$3.89M	$5.27M	$989.00K	$18.49M	-$195.00K
Net Change in Cash	$771.00K	$1.34M	-$2.54M	$16.35M	-$5.15M

Market Snapshot

About

IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment. The company's innovative approach focuses on harnessing the unique properties of gamma-delta T cells, which can recognize and kill cancer cells without requiring HLA matching. IN8bio's lead programs target both hematological malignancies and solid tumors using allogeneic (off-the-shelf) gamma-delta T cell products. The company's technology platform aims to deliver more accessible and affordable cell therapies with reduced risk of graft-versus-host disease and improved manufacturing scalability.